Latest Finance News

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Green Technology Metals (ASX: GT1) sharpens focus on its Seymour Lithium Project amid a lithium price rebound, key permitting progress, and extended C$100 million financing interest from Export Development Canada.

Carma Limited surged past prior year sales with 1,344 units sold, boosted by rapid network expansion and improved reconditioning efficiency, while maintaining a solid cash position.

Neometals Ltd has launched a 1-for-6 entitlement offer at A$0.04 per share alongside a two-tranche placement, targeting a combined A$13 million to advance gold and critical minerals projects.

Culpeo Minerals has restructured its Lana Corina earn-in deal to slash near-term cash outlays and plans a fully funded 4,000m diamond drilling campaign at Vista Montana in Q2 2026, while advancing its Fortuna copper project and streamlining its shareholder base.

Argent BioPharma secured a 48% stake in CannPal Animal Therapeutics, shipped its largest CannEpil® order to Ireland worth A$783,000, and filed a US provisional patent for its NanoBodies platform, underpinning its neuro-immune strategy and commercial growth.

Bannerman Energy has locked in a landmark US$321.5 million strategic investment from CNNC Overseas Limited, enabling debt-free construction of its Etango Uranium Project and setting the stage for a Final Investment Decision in H2 2026.

Volt Resources has secured a major extension and volume increase to its Bunyu graphite offtake agreement while progressing high purity graphite production and downstream refinery development in the US.

Mt Malcolm Mines has delivered a maiden Mineral Resource Estimate of 13,200 ounces across Golden Crown and Dumbarton, while advancing a study on refurbishing a 500,000 tpa CIP plant and preparing for follow-up drilling and funding.

Botanix Pharmaceuticals reported a 5% rise in Sofdra prescriptions in Q3 FY26 despite a dip in net revenue due to insurance deductible resets, strengthened by a $45 million capital raise and a new API supply deal with Piramal.

Sky Metals has bolstered its cash reserves with a $20.5 million raise, backing a major drilling push at Tallebung and expanding exploration at Doradilla, positioning both projects for significant resource growth and development progress.

Syrah Resources delivered a record 24kt graphite production at Balama and secured US$72 million in equity to support medium-term ramp-up and Vidalia commercialisation, navigating a complex US trade environment.